Faruqi & Faruqi Reminds Hims & Hers Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - HIMS

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and unsafe practices related to the promotion of drugs, particularly in connection with a terminated partnership with Novo Nordisk [2][4][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Hims to contact them for discussing legal options [1]. - The firm is investigating claims against Hims and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that Hims engaged in deceptive promotion and selling of illegitimate drugs, risking patient safety and misleading investors about the company's operations and prospects [4]. Group 2: Partnership Termination and Stock Impact - Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and deceptive marketing practices [5]. - Following the announcement, Hims' stock price fell by $22.24, or 34.6%, closing at $41.98 per share, significantly impacting investors [5]. Group 3: Class Action and Lead Plaintiff Information - The court-appointed lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [6]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]. Group 4: Whistleblower Encouragement - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Hims' conduct, including whistleblowers and former employees, to contact the firm [7].